Shire agrees to settlement with US government over ADHD drug marketing

Ireland-headquartered drugmaker Shire (LSE: SHP) said on Friday that it has reached an agreement in principle to pay around $57.5 million to resolve the previously disclosed civil investigation into the company’s US sales and marketing practices relating to the attention-deficit hyperactivity disorder (ADHA) drugs Adderall XR (mixed amphetamine salts), Vyvanse (lisdexamfetamine) and Daytrana (methylphenidate transdermal system).

This seems like a very favorable outcome for Shire relative to most market expectations of a much higher penalty, say analysts at Credit Suisse....

http://www.thepharmaletter.com/file/119766/shire-agrees-to-settlement-with-us-government-over-adhd-drug-marketing.html